Study finds, Efficacy, Safety, and Retreatment Benefit of Mi
Micropulse transscleral cyclophotocoagulation (MP-TSCPC) with a 120-second setting reduces intraocular pressure (IOP) with a 6-month success of 45.5%. Only late (more than 6 mo) failure seem to present a benefit for retreatment.

The purpose of this study was to assess MP-TSCPC efficacy, safety, factors of success, and retreatment benefit in open-angle glaucoma.

Researchers included patients with open-angle glaucoma who were naive of a cycloablative procedure and underwent MP-TSCPC at 2000 mW for 120 seconds. Success was defined as IOP more than 5 and less than 21 mm Hg with IOP reduction more than 20% from baseline, without any retreatment and visual acuity better than negative light perception. MP-TSCPC retreatment was early and late, before and after 6 months postoperatively, respectively.

--94 eyes in 94 patients were included . The mean preoperative IOP was 24.9 mm Hg and was reduced to 18.9 at month 6.

--The success rate decreased progressively over time and reached 45.5% at 6 months.

--Patients with 6-month surgical success had lower mean axial length than others [24.1 vs. 25.5].

--In patients with early and late MP-TSCPC retreatment, the 6-month success rate was 16.7% and 63.6%, respectively.

MP-TSCPC performed with a 120-second setting reduced IOP, with 45.5% success at month 6 and few complications. Axial length was newly described as affecting success, probably linked to the ciliary-body position.